Table 5. Annual Cost Thresholds for Entecavir and Tenofovir.
| Population | Cost-saving (WTP $0) | Highly cost-effective (WTP $6,800) | Cost-effective (WTP $20,400) | |||
|---|---|---|---|---|---|---|
| ETV | TDF | ETV | TDF | ETV | TDF | |
| Non-cirrhotic HBeAg-positive | $522 | $523 | $1,008 | $788 | $1,173 | $986 |
| Non-cirrhotic HBeAg-negative | $378 | $381 | $1,313 | $866 | $1,442 | $1,051 |
| Cirrhotic HBeAg-positive | $899 | $697 | $1,027 | $861 | $1,284 | $1,190 |
| Cirrhotic HBeAg-negative | $886 | $738 | $1,120 | $746 | $1,065 | $762 |
ETV, entecavir; TDF, tenofovir; WTP, willingness to pay.
Threshold between $6,800–20,400 according to the WHO 1-3x GDP for China.